BioSpace News Archive

CoapTech, Inc announced it has been awarded a $50,000 grant by the Children’s Hospital of Philadelphia-based Pennsylvania Pediatric Medical Device Consortium for its PUMA-G Peds System, a device designed to provide a safer way to place feeding tubes in children.

Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognito’s breakthrough, non-invasive disease-modifying therapy for patients with Mild Cognitive Impairment (MCI).

Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced participation in the following upcoming investor conferences.

The global Horseradish Peroxidase (HRP) market research report is a comprehensive report published by Reports and Data that evaluates the market size and share, growth opportunities, risks and limitations, and market growth curve.

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Senores Pharmaceuticals, Inc. announced the launch of Mexiletine Hydrochloride Capsules USP, 150 mg, 200 mg and 250 mg, a therapeutic equivalent version of MEXITIL (Mexiletine Hydrochloride) with one of the top 5 generic pharmaceutical companies in the U.S. market.

Septerna, Inc. today announced its launch and Series A financing of $100 million.

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposium™ in San Diego, Calif.

Excision BioTherapeutics, Inc. today announced the initiation of a first-in-human (FIH) Phase 1/2 clinical trial of EBT-101 in individuals living with human immunodeficiency virus type 1 (HIV).

Apyx Medical Corporation today announced that financial results for the fourth quarter and fiscal year 2021 will be released before the market opens on Thursday, March 17th.